Align Technology, Inc.

Align Technology, Inc. is an American medical device company that designs, manufactures, and markets the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, generating $4.03 billion in revenue in fiscal 2025. The company has treated nearly 23 million patients with Invisalign since inception and operates a global digital platform that connects over 88,000 prescribing doctors, more than 125,000 active scanners, and manufacturing facilities across the Americas, Europe, and Asia.

This is a story about a category-defining franchise that built a $4 billion revenue base by convincing the world that clear plastic trays can do what metal brackets have done for a century — and do it better. Align's Invisalign brand is synonymous with the category it created. But the company that grew revenue at a 29.6% CAGR from 2016 to 2021 has since entered a different phase: revenue has been essentially flat for three years, North American case volumes have stalled, and the stock has fallen roughly 70% from its 2021 peak. The file turns on a single question: whether Align's digital platform, clinical data advantage, and international reach constitute a durable competitive moat that will power the next decade of growth — or whether clear aligners are commoditizing toward a world where Invisalign is merely the most expensive option in a crowded field.

International markets now generate nearly 60% of revenue and are growing double digits, the teen and kids segment continues to take share from wires and brackets, and the Systems & Services business provides a recurring-revenue anchor that no pure-play clear aligner competitor can match. Against that, the North American business — still a third of Clear Aligner revenue — has been declining modestly, competitive intensity is rising from all directions (DSOs negotiating harder, white-label manufacturers proliferating, DTC brands persisting), and the macro environment remains uncertain. How these cross-currents resolve will determine whether Align is a temporarily stalled growth compounder or a structural share donor.